Are NHP studies available under GLP conditions?

Yes. We support both GLP and non-GLP NHP studies. For GLP work, study design and documentation are aligned to your IND-enabling and regulatory strategy under quality systems that follow internationally recognized GLP expectations.

Which NHP species do you use?

Rhesus macaques, cynomolgus macaques, African green monkeys, olive baboons, capuchins, and common marmosets, with custom programs available for additional species on request. Species selection is driven by scientific rationale, compound pharmacology, and regulatory guidance.

Can you support government or biodefense NHP research?

Yes. We have operational experience supporting government-sponsored infectious-disease, biodefense, and vaccine programs. We support BSL-2 and BSL-3 work and can coordinate studies requiring up to BSL-4 containment.

How quickly can a study begin?

It starts with a feasibility discussion covering species, design, cohort size, and timeline. With ample capacity from the largest NHP colony in the United States, we move quickly to get studies underway once the protocol is approved and IACUC approval is obtained where required.

Nonhuman Primate Studies

Translational NHP studies, backed by the largest primate colony in the country.

From early pharmacology through GLP IND-enabling toxicology, led by board-certified veterinarians and decades of primate expertise.

Request a Consultation Submit a Protocol for Review

Study capabilities

The full spectrum of in vivo NHP research.

Pharmacology & PK/PD

Dose-ranging, tolerability, biodistribution, and target engagement.

Safety & Toxicology

Acute and repeat-dose toxicology and safety pharmacology, GLP or non-GLP.

Vaccines & Immunology

Immunogenicity, adjuvant evaluation, and cellular and humoral profiling.

Infectious Disease & Biodefense

Challenge models and countermeasure work, BSL-2 and BSL-3, BSL-4 coordinated.

Surgical & Neuroscience

Interventional models, CNS and behavioral studies, complex procedures.

Custom & Reproductive

Reproductive and developmental biology and sponsor-defined protocols.

Established colonies. The right model.

Rhesus

Macaca mulatta

The most widely characterized NHP model across pharmacology, vaccines, and infectious disease.

Cynomolgus

Macaca fascicularis

A primary species for IND-enabling safety pharmacology and repeat-dose toxicology.

African Green

Chlorocebus aethiops

An established infectious-disease and biodefense model.

Custom programs

On request

Capuchins, baboons, marmosets, and other models through custom programs.

A rhesus macaque in social housing at Alpha Genesis

Welfare and data

Animal care is the foundation of reliable data.

Board-certified veterinarians, species-specific enrichment, social housing, and positive-reinforcement training keep animals stable and study-ready.

AAALACAccredited animal-care program
USDALicensed & registered
GLP/OECDGLP-aligned study support
OLAWAssured under PHS Policy

Our nonhuman primate study capabilities.

Welfare-driven data quality

Enrichment, social housing, and veterinarian-led care produce animals with stable baselines, which supports reproducible data.

Board-certified veterinary depth

Continuous medical oversight from protocol feasibility through terminal procedures, embedded in study conduct rather than consulted only when problems arise.

Large-program experience

Operational experience with large-cohort biodefense, infectious-disease, and vaccine programs and stringent regulatory documentation.

Built for multinational programs

We support sponsors across the United States, Europe, and Asia, with documentation aligned to international regulatory requirements.

Discuss your NHP program.

Share your objectives, species, study type, and timeline. Our scientific and veterinary teams will review feasibility and move quickly to get your program underway.

Request a Consultation Submit a Protocol for Review

Questions

NHP study FAQ

Yes. We support both GLP and non-GLP NHP studies. For GLP work, study design and documentation are aligned to your IND-enabling and regulatory strategy under quality systems that follow internationally recognized GLP expectations.